Denali Advisors LLC Sells 300 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Denali Advisors LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 162,703 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Gilead Sciences makes up approximately 1.4% of Denali Advisors LLC’s portfolio, making the stock its 22nd largest holding. Denali Advisors LLC’s holdings in Gilead Sciences were worth $10,312,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of GILD. First Trust Advisors LP boosted its holdings in Gilead Sciences by 19.2% during the first quarter. First Trust Advisors LP now owns 1,589,328 shares of the biopharmaceutical company’s stock worth $103,322,000 after buying an additional 255,863 shares in the last quarter. Tredje AP fonden lifted its holdings in shares of Gilead Sciences by 14.2% in the first quarter. Tredje AP fonden now owns 145,852 shares of the biopharmaceutical company’s stock valued at $9,482,000 after purchasing an additional 18,188 shares in the last quarter. Intact Investment Management Inc. lifted its holdings in shares of Gilead Sciences by 15.0% in the first quarter. Intact Investment Management Inc. now owns 117,300 shares of the biopharmaceutical company’s stock valued at $7,627,000 after purchasing an additional 15,300 shares in the last quarter. Norinchukin Bank The lifted its holdings in shares of Gilead Sciences by 1.4% in the first quarter. Norinchukin Bank The now owns 311,677 shares of the biopharmaceutical company’s stock valued at $20,262,000 after purchasing an additional 4,335 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Gilead Sciences by 2.5% in the first quarter. Swiss National Bank now owns 4,487,624 shares of the biopharmaceutical company’s stock valued at $291,740,000 after purchasing an additional 108,500 shares in the last quarter. 79.57% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have issued reports on the stock. Wells Fargo & Co raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $68.00 to $88.00 in a report on Monday, July 15th. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, July 12th. Raymond James set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, August 23rd. Cantor Fitzgerald set a $88.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Finally, ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $82.24.



Shares of GILD traded up $0.29 on Wednesday, hitting $61.98. 2,940,834 shares of the stock traded hands, compared to its average volume of 6,684,832. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $78.49 billion, a P/E ratio of 10.08, a P/E/G ratio of 2.97 and a beta of 1.10. The stock’s 50 day moving average is $64.11 and its two-hundred day moving average is $65.34. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $77.06.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.14. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.91 earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 6.66 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.07%. The ex-dividend date of this dividend was Thursday, September 12th. Gilead Sciences’s payout ratio is 40.98%.

In other Gilead Sciences news, Director Olsen Per Wold sold 4,908 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total transaction of $313,670.28. Following the transaction, the director now owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. Insiders have sold 12,716 shares of company stock worth $821,299 in the last three months. Insiders own 0.20% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: How can you know how many shares are floating?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.